Applied BioCode (瑞磁生技 ABC-KY) - Investor Presentation Summary
Date: September 3rd, 2025
Company Overview
- Company Name: Applied BioCode (瑞磁生技)
- Stock Code: ABC-KY (6598)
- Tagline: Barcoded Magnetic Beads | Highly Multiplex Assays
- Mission/Vision: Digital Precision Medicine Platform With FDA Clearance
- Website: www.apbiocode.com
Group Structure
- ABC-KY (6598 瑞磁生技集團):
- Listed on Taiwan Stock Exchange
- Capital: 1,027,775,610 NTD
- Applied BioCode, Inc (Los Angeles)
- 100% owned by ABC-KY
- Approx. 700 ping factory space, 65 employees
- Focus: Multiplex IVD reagent production, R&D, Sales
- 瑞磁生技 (Applied BioCode Taiwan)
- 100% owned by ABC-KY
- 100 ping factory space, 14 employees
- Focus: Core platform production, Asia-Pacific customer service
Leadership Team
- 李家榮, Ph.D.
Co-founder & Chairman- Extensive board experience in biotech IPOs and company acquisitions.
- Holds a Ph.D. in Biochemistry from the State University of New York, Buffalo.
- 何重人, Ph.D.
Co-founder & CEO- Former founder of Maxwell Sensors, holds 15 patents and published 52 articles.
- Ph.D. in Biophysics from the University of Arizona.
- Beth Laderman, Ph.D. – Head of R&D
Former roles at HYCOR Biomedical and Biomerica. - Jim Leigh – VP of Business Development
Extensive experience in customer relations at Renovia and Hologic. - Parisa Hanachi, Ph.D. – VP of Marketing
Former leadership roles at Abbott, Roche Diagnostic, and Thermo Fisher.
Financial Highlights
Revenue Breakdown (2025 H1)
- Human IVD: $4.02M
- Animal Testing: $3.39M
Quarterly Revenue Trend (USD M)
| Quarter | Revenue |
|---|---|
| 2024Q3 | 2.3 |
| 2024Q4 | 2.6 |
| 2025Q1 | 3.6 |
| 2025Q2 | 3.8 |
- CAGR (2020-2024) for Human Diagnostics Business: 27.2%
- Gross Margin: >60%
Market Opportunities
- Target Markets:
- GPP (Gastrointestinal Pathogen Panel): $800M
- RPP (Respiratory Pathogen Panel): $2B
- Total Molecular Diagnostics + Immunoassay: >$70B
- Infectious Disease Testing Market: ~$6B
- MRD Testing Reimbursement (US): $2,000-$3,500 per test (~400,000 annual users)
Business Segments
Dual Growth Engines
1. BMB Platform Licensed to Animal Market
- Licensed to Idexx, the global leader in pet testing (70% market share).
- Applications: Serum, fecal parasite, lymphoma testing.
- Annual project launches and US laboratories adoption.
- Core technology originated in Taiwan.
2. IVD Human Diagnostics
- MDx3000: Fully automated molecular diagnostic instrument with multiplex reagents.
- Reagents Examples:
- GPP (17-item), RPP (20-item), fungi panels, STI + antimicrobial resistance, urinary tract infections.
- Market penetration targets: National labs, third-party labs, large hospitals.
- First Taiwanese reagent company focusing on the US market.
Tumor Liquid Biopsy (MRD Testing)
- Focus on Minimum Residual Disease (MRD).
- 1-5 year follow-up; 2-4 tests per year.
- Utilizes ABC's DLB-PCR offering shorter test time and reduced costs vs. NGS sequencing.
Key Charts and Data
H1 Revenue By Sector (USD M)
| Year | Human IVD | Animal Testing |
|---|---|---|
| 2024H1 | 3.3 | 2.4 |
| 2025H1 | 4.0 (+20%) | 3.4 (+41.8%) |
Competitive Analysis: Luminex vs. Applied BioCode
| Feature | Luminex | Applied BioCode |
|---|---|---|
| Technology | Analog Color | Digital Barcode (✓) |
| Instrument | xMAP | MDx3000 |
| Reagents | GI, RVP | GI, RPP, Fungal, STD (✓) |
| Run Time | 5-6 hours | 3.5 hours (✓) |
| Automation | N | Y (✓) |
| Max Detectable Targets | 300 | 4096 (✓) |
| FDA Clearance | Y | Y |
| Disadvantages | Microfluidic issues | Later market entry |
Tumor Liquid Biopsy: ABC DLB-PCR vs. NGS Sequencing
| Feature | NGS Sequencing | ABC DLB-PCR |
|---|---|---|
| Variants per Test | 200-700 | 10-50 actionable |
| Turnaround Time (TAT) | 7-21 days | 4-6 hours |
| Labor | High | Minimal |
| Cost per Sample (USD) | $1,683-$8,399 | $100-$300 |
Products & Technologies
Core Technology
-
BMB (Digital Barcoded Magnetic Beads):
Revolutionary digital multiplex testing platform. Manufactured using Taiwan semiconductor processes with applications in DNA/Protein Multiplex Assays. -
Real-Time Biomarkers Big Data Analysis:
Enables simultaneous decoding and fluorescence testing.
Key Products & Platforms
MDx3000
- Fully automated for molecular diagnostics.
- Report time: <4 hours.
- FDA clearance and approval with key nucleic acid extraction systems (e.g., KingFisher).
Top Reagents
- GPP - 17-item Gastrointestinal Pathogen Panel.
Pathogens include Campylobacter, Norovirus GI/GII, Salmonella spp., and more. - RPP - 20-item Respiratory Pathogen Panel.
Includes Influenza A/B, Microplasma pneumoniae, and more.
Product Development Timeline
| Year | Key Product Introductions |
|---|---|
| 2019 | MDx3000 |
| 2020 | 20 plex RPP, 17 plex GPP |
| 2021 | SARS-CoV-2 diagnostics |
| 2022 | 7-in-1 Cov-Flu-Plus |
| 2023 | 20 plex Fungal RUO, STI+AMR panels |
| 2025 | UTI panel |
| 2026 | Total AMR |
Outlook & Strategy
Strategic Initiatives
- Expand IVD diagnostic capabilities internationally, targeting North America.
- Develop tumor biopsy capabilities to penetrate the MRD market.
- Continue leveraging animal testing partnerships and technology licensing.
Market Penetration
- Strong adoption by North American laboratories and hospitals.
- Expanded client portfolio includes QDx, Poplar, Baylor, and Tricore.
Intellectual Property
Global Patent Portfolio
- BMB-related patents protect all critical processes from materials to analysis.
- Coverage: US, EU, China.
- Notable Patents:
- US 7,871,770: Barcode Magnetic Beads Structure.
- EP 2342561B1: Biocompatible Polymers.
Disclaimer: This document contains forward-looking information subject to risks and uncertainties.